Get the Stockscreener App
1.16
1.69%
-0.02
Lava Therapeutics Nv stock is traded at $1.16, with a volume of 97,795.
It is down -1.69% in the last 24 hours and down -9.38% over the past month.
See More
Previous Close:
$1.18
Open:
$1.16
24h Volume:
97,795
Relative Volume:
0.25
Market Cap:
$30.51M
Revenue:
$9.06M
Net Income/Loss:
$-50.39M
P/E Ratio:
-0.6042
EPS:
-1.92
Net Cash Flow:
$5.89M
1W Performance:
-10.08%
1M Performance:
-9.38%
6M Performance:
-32.16%
1Y Performance:
-59.58%
1-Day Range:
$1.10
$1.1955
1-Week Range:
$1.10
$1.30
52-Week Range:
$0.8502
$3.57
Lava Therapeutics Nv Stock (LVTX) Company Profile
Name
Lava Therapeutics Nv
Sector
Industry
Phone
31 6 3000 3035
Address
YALELAAN 62, UTRECHT
Compare LVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
1.16 | 30.51M | 9.06M | -50.39M | 5.89M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-25-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-21 | Initiated | JP Morgan | Overweight |
| Apr-19-21 | Initiated | Jefferies | Buy |
| Apr-19-21 | Initiated | SVB Leerink | Outperform |
View All
Lava Therapeutics Nv Stock (LVTX) Latest News
Investors Aren't Buying LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Revenues - simplywall.st
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads after asset cut - Investing.com India
LAVA Therapeutics (NASDAQ:LVTX) Receives Neutral Rating from HC Wainwright - Defense World
Leerink cuts Lava Therapeutics stock target to $1 By Investing.com - Investing.com Canada
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads after asset cut By Investing.com - Investing.com South Africa
Leerink cuts Lava Therapeutics stock target to $1 - Investing.com
JMP maintains LAVA Therapeutics stock Market Perform rating By Investing.com - Investing.com Australia
JMP maintains LAVA Therapeutics stock Market Perform rating - Investing.com
Lava Therapeutics Reports 2024 Financial Results - TipRanks
LAVA Therapeutics NV earnings beat by $0.16, revenue topped estimates - Investing.com Australia
LAVA Therapeutics N.V. (LVTX) reports earnings - Quartz
LAVA Therapeutics NV SEC 10-K Report - TradingView
LAVA Therapeutics NV reports results for the quarter ended December 31Earnings Summary - TradingView
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - GlobeNewswire
LAVA Therapeutics Q4 Basic EPS USD -0.14 - MarketScreener
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads amid pipeline shifts By Investing.com - Investing.com South Africa
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads amid pipeline shifts - Investing.com
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang - Benzinga
This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
LAVA Therapeutics Reviews Strategic Alternatives, Announces 30% Staff Cut - Nasdaq
LAVA Therapeutics Announces Restructuring Plan for 2025 - TipRanks
LAVA Announces Evaluation of Strategic Options - GlobeNewswire
Can LAVA Therapeutics Find a Buyer? Company Cuts 30% of Staff While Exploring Strategic Options - StockTitan
LVTX stock touches 52-week low at $0.88 amid market challenges - Investing.com Australia
LVTX stock touches 52-week low at $0.88 amid market challenges By Investing.com - Investing.com South Africa
LAVA Therapeutics (NASDAQ:LVTX) Stock Price Down 4.6% – Here’s What Happened - Defense World
RNA Editing Market Top Companies StudyQIAGEN N.V., UniquQuire - openPR
LAVA Therapeutics begins trial for cancer treatment - Investing.com India
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - GlobeNewswire
LAVA Therapeutics Initiates Phase 1 Trial for Novel Leukemia Treatment LAVA-1266 - StockTitan
LAVA Therapeutics NV (LVTX)’S -5.56% Retreat Makes It Worth Considering Again - Stocks Register
LAVA Therapeutics NV Files 8-K with SEC, Transitioning to U.S. Domestic Issuer Status - Defense World
LVTX stock touches 52-week low at $0.95 amid market challenges - Investing.com
H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization - Investing.com
LAVA Therapeutics stock hits 52-week low at $0.98 - Investing.com
Lava Therapeutics' SWOT analysis: stock faces challenges after key asset discontinuation - Investing.com
Research Analysts Issue Forecasts for LVTX Q1 Earnings - Defense World
LAVA Therapeutics (NASDAQ:LVTX) Rating Lowered to “Hold” at Leerink Partnrs - Defense World
Leerink Partners Downgrades LAVA Therapeutics N.V. (LVTX) - MSN
Leerink cuts Lava Therapeutics stcok to Market Perform By Investing.com - Investing.com Nigeria
Leerink cuts Lava Therapeutics stcok to Market Perform - Investing.com India
Lava Therapeutics Nv Stock (LVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):